Advanced Breast Cancer

Palbociclib + Letrozole Improve Survival in Breast Cancer

Palbociclib + Letrozole Improve Survival in Breast Cancer

Pfizer announced that the Phase 2 PALOMA-1 trial met its primary endpoint by achieving a statistically significant and clinically meaningful improvement in progression-free survival for the combination of palbociclib and letrozole vs. letrozole alone in postmenopausal women with ER+, HER2- advanced breast cancer.

Next post in Breast Cancer